X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall

MT Newswires Live

2025/02/06

X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.

The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.

X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.

The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.

Shares of X4 fell 6% in recent trading.

Price: 0.58, Change: -0.04, Percent Change: -6.00

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2509082212"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509082212\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509082212?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509082212","market":"hk","top_or_hot":-1,"title":"X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.</p><p>The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.</p><p>X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.</p><p>The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.</p><p>Shares of X4 fell 6% in recent trading.</p><p>Price: 0.58, Change: -0.04, Percent Change: -6.00</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nX4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-06 23:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.</p><p>The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.</p><p>X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.</p><p>The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.</p><p>Shares of X4 fell 6% in recent trading.</p><p>Price: 0.58, Change: -0.04, Percent Change: -6.00</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509082212","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509082212","pubTimestamp":1738856227,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.The compa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XFOR":"X4制药"},"translate_title":"X4 Pharmaceuticals裁员30%，关闭奥地利工厂；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XFOR":0.9},"content_text":"X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.Shares of X4 fell 6% in recent trading.Price: 0.58, Change: -0.04, Percent Change: -6.00","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}